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Background
Most physicians are familiar with simple mendelian genetics wherein a rare mutation (by definition, one that occurs in Ͻ1% of the population) in a gene causes a dramatic change in protein concentration or function that is usually both necessary and sufficient to cause the disease. These heritable diseases are disproportionately con-centrated within families that carry the mutation, and environmental factors typically play a small or nonexistent role. Examples of cardiovascular mendelian disorders include familial hypercholesterolemia, familial hypertrophic cardiomyopathy, Marfan syndrome, and congenital long-QT syndrome.
Unfortunately, but perhaps not unexpectedly, most of the common diseases in cardiology do not obey traditional mendelian genetics. These complex genetic diseases result from the combination of multiple heritable and environmental factors ( Table 1 ). The associated genetic variants tend to be more common (Ͼ1% prevalence) and by convention are called polymorphisms (often single nucleotide polymorphisms or SNPs) rather than mutations. Moreover, the effect of each SNP on an individual's phenotype tends to be far more modest and may not be necessary or sufficient to cause the disease (Figure 1 ).
Identifying Gene Variants That Contribute to Disease
Genetic epidemiology studies typically rely on the coinheritance of known polymorphic DNA markers with nearby but unknown disease-causing variants. Traditionally, inheritance studies, which are performed in families and utilize linkage analysis, have been used to investigate monogenic, mendelian disorders. 1 DNA markers close to the disease-causing gene are less likely to be separated by a recombination event than are markers far away from the disease-causing gene and therefore are more likely to be transmitted together from parent to offspring (Figure 2A ). By gathering data on the inheritance patterns of markers and disease states within families, the distance between markers and the disease-causing gene can be estimated and thus the location of the disease-causing gene inferred. Although this approach has led to the discovery of many genes that are linked to human diseases, it has proven less useful in complex genetic disorders, 2 in part because of reduced power to detect frequently occurring markers that convey only modest effects and in part because of phenocopies.
In contrast, association studies investigate complex genetic disorders using unrelated individuals, testing for nonindependence between a genotype and the disease phenotype: if a genotype is truly related to a disease, it will be found more frequently in individuals with the disease than in those without the disease ( Figure 2B ). Within association studies, one can opt to genotype either putative causal variants (ie, direct association) or polymorphic markers that one hopes are close to the true disease-causing variant (indirect association). 3 In the former case, the investigator typically selects functional SNPs in biologically relevant genes. Although intuitively appealing, such an approach is constrained by the current biological knowledge base and involves many assumptions. For that reason, others have advocated employing a compre-hensive genome-wide scan using random DNA markers that blanket the entire genome. The cataloguing of Ϸ10 million SNPs 4 and advances in high-throughput genotyping, including high-density DNA microarrays, 5 make such genome-wide scans possible, albeit daunting. Akin to linkage analysis, a disease-causing variant that arose many generations ago in close proximity to a DNA marker will be coinherited with that marker so strongly and persistently that it ultimately leads to an association at the population level (termed linkage disequilibrium) due to shared common ancestry. 6 Of note, haplotypes are linear arrangements of adjacent SNPs on the same chromosome and offer the potential to improve both genetic precision and genotyping efficiency. In association studies, recombination between the marker SNP and the diseasecausing variant will erode the linkage disequilibrium in some patients and lead to confusing results. In contrast, a haplotype that is defined by the presence of 2 SNPs flanking the disease- The presence of the variant allele causes a shift in the distribution of the trait toward the disease threshold. In the case of a simple mendelian disorder (eg, sickle cell anemia), a rare mutation (substitution of valine for glutamic acid in the ␤-globin chain) causes a very large shift in the trait (solubility of deoxygenated hemoglobin), which is sufficient to cause the disease. In contrast, for a complex disorder (eg, MI), a polymorphism (eg, in a gene encoding a platelet receptor) causes a more subtle shift in the trait (platelet aggregability) that increases the risk of the disease but alone is neither necessary nor sufficient, and the majority of individuals with this polymorphism will never develop the disease. Adapted with permission from Nature. 2000;405:847-856.
causing variant would be more likely to remain linked with the diseasecausing variant than would either SNP alone. Moreover, although many SNPs may fall within a haplotype, because of linkage disequilibrium it is necessary to genotype only a few SNPs (socalled haplotype tagging SNPs) to uniquely identify the haplotype. This approach permits a substantial reduction in genotyping effort 7 and consequently reduces costs and the number of independent variables analyzed, thereby profoundly affecting the statistical analyses. To that end, the International HapMap project has reported the construction of a genome-wide map of linkage disequilibrium in multiple populations. 8
Potential Pitfalls in Genetic Studies
Genetic epidemiology studies have several special limitations (Table 2) , including genetic heterogeneity (different genotypes leading to the same phenotype), phenotypic heterogeneity (variability in expressivity or clinical manifestations of a genetic disease), phenotypic imprecision (combining phenotypes with potentially different genetic contributions), phenocopy (a phenotype that mimics the genetically caused phenotype of interest), and population stratification. The latter is a special type of confounding that can occur whenever a non-ethnically homogeneous population is studied. If an ethnic group has a higher frequency of a disease for nongenetic reasons, any genetic variant that occurs more frequently in that ethnic group, even if it is not causally linked to the disease, will spuriously appear to be associated with the disease. Type I statistical errors (falsepositives) are a major problem due to multiple testing. With 30 000 genes and 10 million SNPs, the number of possible association tests is enormous. Techniques have been developed to control experiment-wise error rates that include setting the false discovery rate and performing permutation testing. Replication of results in an independent population before proclaiming a confirmed association remains the best approach 9 and one that is now required by leading journals. Type II statistical errors (false-negatives) are also a problem due to small sample size. The excess risk or benefit associated with a polymorphism may be modest in magnitude and therefore only detectable with large studies on the order of at least 1000 case-control pairs, although this conventional wisdom has recently been challenged. 10 Finally, it is important to remember that statistical association is not proof of causality. A polymorphism associated with a disease is unlikely to be the causal variant but rather to be in strong linkage disequilibrium with the true causal variant within the same gene or even potentially in nearby genes. This can lead to inconsistencies between studies if the causal variants arose independently in different populations.
Examples of Genetic Approaches to Coronary Artery Disease Linkage Analysis
In an attempt to apply traditional linkage analysis to the complex genetic disorder of coronary artery disease, researchers performed a genome-wide scan on a single family with an apparent autosomal dominant pattern of coronary artery disease. They found significant linkage with a marker in a region that contains the myocyte enhancer factor-2 family (MEF2A) gene. 11 However, a different research group was not able to replicate this finding in individuals with sporadic MI. 12 Other groups have used linkage analysis to large numbers of multiplex families with a variety of coronary heart disease phenotypes. [13] [14] [15] [16] Each group has found significant linkage but to different chromosomal regions. Whether the different loci identified in each study reflect phenotypic imprecision or false-positive results remains unclear.
Multilocus Candidate Gene Studies
In 2002, one of the largest genetic association studies for MI was published, involving 112 polymorphisms in 71 candidate genes in 5061 unrelated individuals. 17 The investigators conducted a staged approach, setting a more modest threshold for identifying candidate SNPs in a small cohort and then a more stringent threshold for validating the associations in a second, larger cohort. In analyses stratified by gender, their approach yielded 1 SNP in men (in the connexin 37 gene) and, Phenocopy: a phenotype that mimics the genetically caused phenotype of interest
TABLE 2. Limitations of Genetic Association Studies

Statistical issues
Confounding: a type of bias in which an artefactual association between a predictor and an outcome is caused by a third factor independently associated with both the predictor and the outcome Population stratification: a non-ethnically homogeneous study population in which one ethnic group is overrepresented in cases and also happens to have a higher prevalence of certain non-disease-causing genetic variants
Multiple testing: analyses that, without proper adjustment, predispose to false-positive studies (type I error)
Small sample size: a design flaw that predisposes to false-negative studies (type II error)
Publication bias: the observation that positive studies are more likely to be published than negative studies; this can lead to inflated effect estimates in meta-analyses surprisingly, 2 other SNPs in women (in the PAI-1 and stromelysin genes). Several other, smaller multilocus studies have been published, but none of these studies has identified the same genetic variants as associated with MI. Of note, one of the groups that found linkage between the gene encoding 5-lipoxygenase activating protein and coronary heart disease 16 has subsequently reported an association between a haplotype spanning the gene encoding leukotriene A4 hydrolase and MI. 18 Although it is intriguing that these genes encode proteins within the same biochemical pathway, it is notable that the associations were found in different populations, one white and one black.
Genome-Wide Association Studies
A group in Japan examined 92 788 SNPs in a large case-control study involving 1133 cases with MI and 1006 controls. 19 They identified 3 SNPs in the lymphotoxin-␣ gene that were strongly associated with MI. Subsequent molecular biology studies demonstrated that the variants were associated with transcriptional and functional changes in lymphotoxin-␣. Another group of researchers performed a genome-wide association study examining 11 053 SNPs in 6891 genes, using 3 sequential studies to validate their findings. 20 They found variants in 4 genes, none previously implicated in MI, that were consistently associated with MI in all 3 stages. As with the multilocus studies, no 2 groups have identified the same variant.
Pharmacogenomics
Investigators have explored the interaction between genetic variants and response to cardiovascular drugs with the hope of more precisely defining efficacy and safety profiles. To that end, polymorphisms in the genes encoding HMG-CoA reductase, 21 apolipoprotein E, 22 and the ADAMTS-1 metalloproteinase 23 appear to predict the magnitude of change in lipid levels and/or the reduction in adverse clinical outcomes in response to statin therapy. Polymorphisms in the genes that encode ␤-adrenergic receptors have been associated not only with the risk of developing heart failure 24 but also with improvement in ejection fraction in response to ␤-blocker therapy. 25 Finally, the anticoagulant effect of a dose of warfarin is affected by polymorphisms in the genes that encode CYP2C9 and vitamin K epoxide reductase complex 1. 26, 27 
Conclusions
Learning from early forays, researchers are now designing better genetic epidemiological studies to detect the subtle but likely important contribution of genetic variation to common cardiovascular diseases. The hallmarks of a good genetic association study include accurate and comprehensive genotyping, evaluation of a large number of carefully phenotyped patients, and replication of significant associations. The requisite scope of such studies underscores the need for a multidisciplinary and multicenter collaborative approach. With the pace of advances into the molecular basis for atherothrombosis, management of patients such as the one described in our case study will, in the near future, likely include genetic analysis to improve risk stratification and tailor therapy appropriately.
